Immune thrombocytopenia （ITP） is an autoimmune disorder characterized by continuously decrease of platelet and the skin mucous membrane bleeding. The pathogenesis of ITP remains enigmatic; The currently used drugs can be divided into first - line and second - line that are not specific and may cause many side effects, However, the emerging of new biodrugs brings new hope for the management of ITP In this review, we summarized the research advances of TPO analogues; antibodies, blocking agents of co - stimulatory signals, ...
